Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) EV-to-EBIT : -6.42 (As of May. 11, 2024)

Sucampo Pharmaceuticals EV-to-EBIT Chart

Sucampo Pharmaceuticals Annual Data
	Trend	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16
EV-to-EBIT		Get a 7-Day Free Trial					19.41	31.32	19.85	18.42	18.91

Sucampo Pharmaceuticals Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
EV-to-EBIT	Get a 7-Day Free Trial															15.88	18.91	11.16	-5.30	-5.73

Competitive Comparison of Sucampo Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sucampo Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's EV-to-EBIT falls into.

Sucampo Pharmaceuticals EV-to-EBIT Calculation

Sucampo Pharmaceuticals's EV-to-EBIT for today is calculated as:

Sucampo Pharmaceuticals's current Enterprise Value is $849.0 Mil.
Sucampo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-132.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sucampo Pharmaceuticals  (NAS:SCMP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sucampo Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

Sucampo Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2017 was $757.2 Mil.
Sucampo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-132.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sucampo Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description